Heron Therapeutics (NASDAQ:HRTX) Shares Cross Above 200-Day Moving Average – Time to Sell?

Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.76 and traded as high as $1.81. Heron Therapeutics shares last traded at $1.78, with a volume of 1,155,217 shares changing hands.

Wall Street Analyst Weigh In

Several analysts recently commented on HRTX shares. Needham & Company LLC restated a “buy” rating and set a $4.00 price target on shares of Heron Therapeutics in a research report on Wednesday, December 4th. StockNews.com lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 29th.

Heron Therapeutics Stock Performance

The business’s 50 day simple moving average is $1.65 and its 200 day simple moving average is $1.75.

Institutional Investors Weigh In On Heron Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. raised its stake in shares of Heron Therapeutics by 295.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company’s stock valued at $411,000 after acquiring an additional 154,487 shares during the period. Principal Financial Group Inc. raised its stake in shares of Heron Therapeutics by 456.5% in the 3rd quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 84,205 shares during the period. Verition Fund Management LLC raised its stake in shares of Heron Therapeutics by 340.0% in the 3rd quarter. Verition Fund Management LLC now owns 108,115 shares of the biotechnology company’s stock valued at $215,000 after acquiring an additional 83,542 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Heron Therapeutics by 16.0% in the second quarter. The Manufacturers Life Insurance Company now owns 45,771 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 6,328 shares in the last quarter. Finally, Congress Park Capital LLC grew its holdings in shares of Heron Therapeutics by 24.1% in the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock valued at $3,757,000 after purchasing an additional 477,417 shares in the last quarter. 80.01% of the stock is owned by hedge funds and other institutional investors.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.